Author details

Full Name

Federica Piccioni

Affiliation

ORCID

Career Start Year

2001

Papers

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
36796362	Natural variation in gene expression and viral susceptibility revealed by neural progenitor cell villages.		2023
36398965	Transcriptional Antagonism by CDK8 Inhibition Improves Therapeutic Efficacy of MEK Inhibitors.	Cancer Res	2023
37286821	Genome-wide pooled CRISPR screening in neurospheres.	Nat Protoc	2023
34531254	An <i>In Vivo</i> CRISPR Screening Platform for Prioritizing Therapeutic Targets in AML.	Cancer Discov	2022
35773251	Allosteric inhibition of PPM1D serine/threonine phosphatase via an altered conformational state.	Nat Commun	2022
36305736	BAF Complex Maintains Glioma Stem Cells in Pediatric H3K27M Glioma.	Cancer Discov	2022
35437317	Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancer.	Nat Cancer	2022
35537449	NSD1 mediates antagonism between SWI/SNF and polycomb complexes and is required for transcriptional activation upon EZH2 inhibition.	Mol Cell	2022
35353015	Cell Painting predicts impact of lung cancer variants.	Mol Biol Cell	2022
35332332	Systematic identification of biomarker-driven drug combinations to overcome resistance.	Nat Chem Biol	2022
35105861	PPM1D mutations are oncogenic drivers of de novo diffuse midline glioma formation.	Nat Commun	2022
34373451	Integrative oncogene-dependency mapping identifies RIT1 vulnerabilities and synergies in lung cancer.	Nat Commun	2021
33534641	Predicting cell health phenotypes using image-based morphology profiling.	Mol Biol Cell	2021
34272366	Structure of PDE3A-SLFN12 complex reveals requirements for activation of SLFN12 RNase.	Nat Commun	2021
33619228	Comprehensive Mutational Analysis of the BRCA1-Associated DNA Helicase and Tumor-Suppressor FANCJ/BACH1/BRIP1.	Molecular Cancer Research	2021
33510483	Noncanonical open reading frames encode functional proteins essential for cancer cell survival.	Nat Biotechnol	2021
34260938	Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q.	Cell Rep	2021
34329586	TRIM8 modulates the EWS/FLI oncoprotein to promote survival in Ewing sarcoma.	Cancer Cell	2021
33326793	Synthetic Lethal Interaction between the ESCRT Paralog Enzymes VPS4A and VPS4B in Cancers Harboring Loss of Chromosome 18q or 16q.	Cell Rep	2020
32371585	A Genome-scale CRISPR Screen Identifies the ERBB and mTOR Signaling Networks as Key Determinants of Response to PI3K Inhibition in Pancreatic Cancer.	Mol Cancer Ther	2020
31771968	Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.	Cancer Discov	2020
31668800	Genotype-Fitness Maps of EGFR-Mutant Lung Adenocarcinoma Chart the Evolutionary Landscape of Resistance for Combination Therapy Optimization.		2020
32483149	A genome-wide gain-of-function screen identifies CDKN2C as a HBV host factor.	Nat Commun	2020
32723837	Acquired FGFR and FGF Alterations Confer Resistance to Estrogen Receptor (ER) Targeted Therapy in ER<sup>+</sup> Metastatic Breast Cancer.	Clin Cancer Res	2020
31462500	Pooled Genomic Screens Identify Anti-apoptotic Genes as Targetable Mediators of Chemotherapy Resistance in Ovarian Cancer.	Mol Cancer Res	2019
31747605	CREB5 Promotes Resistance to Androgen-Receptor Antagonists and Androgen Deprivation in Prostate Cancer.	Cell Rep	2019
31730859	A Compendium of Genetic Modifiers of Mitochondrial Dysfunction Reveals Intra-organelle Buffering.	Cell	2019
31577942	Synthetic Lethal Interaction of SHOC2 Depletion with MEK Inhibition in RAS-Driven Cancers.	Cell Rep	2019
30397176	A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.	Clin Cancer Res	2019
31543463	Mitochondrial Reprogramming Underlies Resistance to BCL-2 Inhibition in Lymphoid Malignancies.	Cancer Cell	2019
30819666	A Functional Landscape of Resistance to MEK1/2 and CDK4/6 Inhibition in NRAS-Mutant Melanoma.	Cancer Res	2019
31160565	Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastoma.	Nat Commun	2019
29654068	RAS-MAPK Reactivation Facilitates Acquired Resistance in <i>FGFR1</i>-Amplified Lung Cancer and Underlies a Rationale for Upfront FGFR-MEK Blockade.	Mol Cancer Ther	2018
30224644	Mutational processes shape the landscape of TP53 mutations in human cancer.	Nat Genet	2018
30537514	Resistance to Epigenetic-Targeted Therapy Engenders Tumor Cell Vulnerabilities Associated with Enhancer Remodeling.	Cancer Cell	2018
30575746	Optimized libraries for CRISPR-Cas9 genetic screens with multiple modalities.	Nat Commun	2018
30232005	Regulation of Cellular Heterogeneity and Rates of Symmetric and Asymmetric Divisions in Triple-Negative Breast Cancer.	Cell Rep	2018
29259014	ER Stress Signaling Promotes the Survival of Cancer "Persister Cells" Tolerant to EGFR Tyrosine Kinase Inhibitors.	Cancer Res	2018
29337374	Pooled Lentiviral-Delivery Genetic Screens.	Curr Protoc Mol Biol	2018
28178529	ATXN1L, CIC, and ETS Transcription Factors Modulate Sensitivity to MAPK Pathway Inhibition.	Cell Rep	2017
28561737	Synergistic interactions with PI3K inhibition that induce apoptosis.	Elife	2017
29195078	A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.	Cell	2017
29232558	High-throughput Phenotyping of Lung Cancer Somatic Mutations.	Cancer Cell	2017
27684187	Genetic and Proteomic Interrogation of Lower Confidence Candidate Genes Reveals Signaling Networks in Î²-Catenin-Active Cancers.	Cell Syst	2016
27147599	Systematic Functional Interrogation of Rare Cancer Variants Identifies Oncogenic Alleles.	Cancer Discov	2016
27478040	High-throughput Phenotyping of Lung Cancer Somatic Mutations.	Cancer Cell	2016
27760319	Phenotypic Characterization of a Comprehensive Set of MAPK1/ERK2 Missense Mutants.	Cell Rep	2016
26197079	Morphological Profiles of RNAi-Induced Gene Knockdown Are Highly Reproducible but Dominated by Seed Effects.	PLoS One	2015
25759024	A functional landscape of resistance to ALK inhibition in lung cancer.	Cancer Cell	2015
24584072	An epigenetic mechanism of resistance to targeted therapy in T cell acute lymphoblastic leukemia.	Nat Genet	2014